Protein kinase C has been seen as a tumor promoter, however, PKC inhibitors have not been successful in clinical trials and recent evidences (2015) suggest that this may be due to a duality of cPKC functioning both as a tumor suppressor and promoter1. This evidence concerns the gene PRRT2 and neoplasm.